Death effector domain-containing proteins

Cellular and Molecular Life Sciences

Volumn 66, Issue 5, 2009, Pages 814-830

  Valmiki, M Gudur ^a,b   Ramos, J W ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Apoptosis; Caspase; Death effector domain; FADD; Migration; Proliferation; Signal transduction

Indexed keywords

CASPASE 10; CASPASE 8; DEATH EFFECTOR DOMAIN CONTAINING DNA BINDING PROTEIN; DEATH EFFECTOR DOMAIN CONTAINING DNA BINDING PROTEIN 2; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; PHOSPHOPROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; ISOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; EMBRYO DEVELOPMENT; GLIOBLASTOMA; GLIOMA; HUMAN; HUNTINGTON CHOREA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOBLASTOMA; LYMPHOPROLIFERATIVE DISEASE; NEUROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; THYROID CANCER; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; MORPHOGENESIS; PHYSIOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

PISUM SATIVUM;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; HUMANS; MODELS, MOLECULAR; MORPHOGENESIS; PROTEIN CONFORMATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 63049089877     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8489-0     Document Type: Review

References (165)

1. Zimmermann K. C., Bonzon C., and Green D. R. (2001) The machinery of programmed cell death. Pharmacol. Ther. 92, 57-70.
2. Degterev A. and Yuan J. (2008) Expansion and evolution of cell death programmes. Nat. Rev Mol. Cell Biol. 9, 378 -390.
3. Budd R. C., Yeh W. C., and Tschopp J. (2006) cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 6, 196-204.
4. Kitsberg D., Formstecher E., Fauquet M., Kubes M., Cordier J., Canton B., Pan G., Rolli M., Glowinski J., and Chneiweiss H. (1999) Knock-out of the neural death effector domain protein PEA-15 demonstrates that its expression protects astrocytes from TNFalpha-induced apoptosis. J. Neurosci. 19, 8244-8251.
5. Condorelli G., Vigliotta G., Cafieri A., Trencia A., Andalo P., Oriente F., Miele C., Caruso M., Formisano P., and Beguinot F. (1999) PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 18, 4409-4415.
6. Park S. M., Schickel R., and Peter M. E. (2005) Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr. Opin. Cell Biol. 17, 610-616.
7. Formstecher E., Ramos J. W., Fauquet M., Calderwood D. A., Hsieh J. C., Canton B., Nguyen X. T., Barnier J. V., Camonis J., Ginsberg M. H., and Chneiweiss H. (2001) PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev. Cell 1, 239-250.
8. Kataoka T., Budd R. C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., and Tschopp J. (2000) The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 10, 640-648.
9. Stupack D. G., Teitz T., Potter M. D., Mikolon D., Houghton P. J., Kidd V. J., Lahti J. M., and Cheresh D. A. (2006) Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439, 95-99.
10. Frisch S. M. (2008) Caspase-8: fly or die. Cancer Res. 68, 4491 -4493.
11. Reed J. C., Doctor K. S., and Godzik A. (2004) The domains of apoptosis: a genomics perspective. Sci. STKE. 2004, re9.
12. Acehan D., Jiang X., Morgan D. G., Heuser J. E., Wang X., and Akey C. W. (2002) Three-Dimensional Structure of the Apoptosome: Implications for Assembly, Procaspase-9 Binding, and Activation. Molecular Cell 9, 423-432.
13. Weber C. H. and Vincenz C. (2001) The death domain superfamily: a tale of two interfaces? Trends in Biochemical Sciences 26, 475-481.
14. Fairbrother W. J., Gordon N. C., Humke E. W., O'Rourke K. M., Starovasnik M. A., Yin J. P., and Dixit V. M. (2001) The PYRIN domain: a member of the death domain-fold super- family. Protein Sci. 10,1911-1918.
15. Weber C. H. and Vincenz C. (2001) The death domain superfamily: a tale of two interfaces? Trends in Biochemical Sciences, 26, 475-481.
16. Qin H., Srinivasula S. M., Wu G., Fernandes-Alnemri T., Alnemri E. S., and Shi Y. (1999) Structural basis of procaspase-9 recruitment by the apoptotic protease-activat-ing factor 1. Nature 399, 549-557.
17. Xiao T., Towb P., Wasserman S. A., and Sprang S. R. (1999) Three-Dimensional Structure of a Complex between the Death Domains of Pelle and Tube. Cell 99, 545-555.
18. Eberstadt M., Huang B., Chen Z., Meadows R. P., Ng S. C., Zheng L., Lenardo M. J., and Fesik S. W. (1998) NMR structure and mutagenesis of the FADD (Mort1) deatheffector domain. Nature 392, 941 -945.
19. Kaufmann M., Bozic D., Briand C., Bodmer J. L., Zerbe O., Kohl A., Tschopp J., and Grutter M. G. (2002) Identification of a basic surface area of the FADD death effector domain critical for apoptotic signaling. FEBS Lett. 527, 250-254.
20. Carrington P. E., Sandu C., Wei Y., Hill J. M., Morisawa G., Huang T., Gavathiotis E., Wei Y., and Werner M. H. (2006) The structure of FADD and its mode of interaction with procaspase-8. Mol. Cell 22, 599-610.
21. Li F. Y., Jeffrey P. D., Yu J. W., and Shi Y. (2006) Crystal structure of a viral FLIP: insights into FLIP-mediated inhibition of death receptor signaling. J. Biol. Chem. 281, 2960-2968.
22. Garvey T. L., Bertin J., Siegel R. M., Wang G. H., Lenardo M. J., and Cohen J. I. (2002) Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function. J. Virol. 76, 697-706.
23. Muppidi J. R., Lobito A. A., Ramaswamy M., Yang J. K., Wang L., Wu H., and Siegel R. M. (2006) Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ. 13, 1641-1650.
24. Hill J. M., Morisawa G., Kim T., Huang T., Wei Y., Wei Y., and Werner M. H. (2004) Identification of an expanded binding surface on the FADD death domain responsible for interaction with CD95/Fas. J. Biol. Chem. 279, 1474-1481.
25. Yang J. K., Wang L., Zheng L., Wan F., Ahmed M., Lenardo M. J., and Wu H. (2005) Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition. Mol. Cell 20, 939-949.
26. Sandu C., Morisawa G., Wegorzewska I., Huang T., Arechiga A. F., Hill J. M., Kim T., Walsh C. M., and Werner M. H. (2006) FADD self-association is required for stable interaction with an activated death receptor. Cell Death Differ. 13, 2052-2061.
27. Ueffing N., Keil E., Freund C., Kuhne R., Schulze-Osthoff K., and Schmitz I. (2008) Mutational analyses of c-FLIPR., the only murine short FLIP isoform, reveal requirements for DISC recruitment. Cell Death Differ. 15,773-782.
28. Aravind L., Dixit V. M., and Koonin E. V. (2001) Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science 291, 1279-1284.
29. Hofmann K., Bucher P., and Tschopp J. (1997) The CARD domain: a new apoptotic signalling motif. Trends Biochem. Sci. 22, 155-156.
30. (2004) Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution. Nature 432, 695 -716.
31. Barnhart B. C., Alappat E. C., and Peter M. E. (2003) The CD95 type I/type II model. Semin. Immunol. 15, 185-193.
32. Peter M. E., Budd R. C., Desbarats J., Hedrick S. M., Hueber A. O., Newell M. K., Owen L. B., Pope R. M., Tschopp J., Wajant H., Wallach D., Wiltrout R. H., Zornig M., and Lynch D. H. (2007) The CD95 receptor: apoptosis revisited. Cell 129, 447-450.
33. Thomas L. R., Stillman D. J., and Thorburn A. (2002) Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen. J. Biol. Chem. 277, 34343-34348.
34. Chinnaiyan A. M., Tepper C. G., Seldin M. F., O'Rourke K., Kischkel F. C., Hellbardt S., Krammer P. H., Peter M. E., and Dixit V. M. (1996) FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor- induced apoptosis. J. Biol. Chem. 271, 4961-4965.
35. Chaudhary P. M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7, 821 -830.
36. Siegel R. M., Muppidi J. R., Sarker M., Lobito A., Jen M., Martin D., Straus S. E., and Lenardo M. J. (2004) SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167, 735-744.
37. Salvesen G. S. and Riedl S. J. (2008) Caspase mechanisms. Adv. Exp. Med. Biol. 615, 13-23.
38. Ho P. K. and Hawkins C. J. (2005) Mammalian initiator apoptotic caspases. FEBS J. 272, 5436-5453.
39. Kischkel F. C., Lawrence D. A., Tinel A., LeBlanc H., Virmani A., Schow P., Gazdar A., Blenis J., Arnott D., and Ashkenazi A. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639-46646.
40. Roth W., Stenner-Liewen F., Pawlowski K., Godzik A., and Reed J. C. (2002) Identification and characterization of DEDD2, a death effector domain-containing protein. J. Biol. Chem. 277, 7501 -7508.
41. Stegh A. H., Schickling O., Ehret A., Scaffidi C., Peterhansel C., Hofmann T. G., Grummt I., Krammer P. H., and Peter M. E. (1998) DEDD., a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J. 17, 5974-5986.
42. Schickling O., Stegh A. H., Byrd J., and Peter M. E. (2001) Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and inhibition of RNA polymerase I dependent transcription. Cell Death Differ. 8, 1157-1168.
43. Zheng L., Schickling O., Peter M. E., and Lenardo M. J. (2001) The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J. Biol. Chem. 276,31945 -31952.
44. Lee J. C., Schickling O., Stegh A. H., Oshima R. G., Dinsdale D., Cohen G. M., and Peter M. E. (2002) DEDD regulates degradation of intermediate filaments during apoptosis. J. Cell Biol. 158,1051-1066.
45. Alcivar A., Hu S., Tang J., and Yang X. (2003) DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene 22, 291 -297.
46. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J. L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L. E., and Tschopp J. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195.
47. Hu S., Vincenz C., Ni J., Gentz R., and Dixit V. M. (1997) I- FLICE., a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272, 17255-17257.
48. Hu S., Vincenz C., Buller M., and Dixit V. M. (1997) A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1- induced apoptosis. J. Biol. Chem. 272, 9621 -9624.
49. Chang D. W., Xing Z., Pan Y., geciras-Schimnich A., Barnhart B. C., Yaish-Ohad S., Peter M. E., and Yang X. (2002) c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 21, 3704-3714.
50. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. (2001) NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 21, 5299-5305.
51. Xiao C., Yang B. F., Asadi N., Beguinot F., and Hao C. (2002) TRAIL-induced death-inducing signaling complex (DISC) and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 277, 25020-25025.
52. Renganathan H., Vaidyanathan H., Knapinska A., and Ramos J. W. (2005) Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem. J. 390,729-735.
53. Trencia A., Perfetti A., Cassese A., Vigliotta G., Miele C., Oriente F., Santopietro S., Giacco F., Condorelli G., For- misano P., and Beguinot F. (2003) Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol. Cell Biol. 23, 4511-4521.
54. Kubes M., Cordier J., Glowinski J., Girault J. A., and Chneiweiss H. (1998) Endothelin induces a calcium-dependent phosphorylation of PEA-15 in intact astrocytes: identification of Ser104 and Ser116 phosphorylated, respectively, by protein kinase C and calcium/calmodulin kinase II in vitro. J. Neurochem. 71,1307-1314.
55. Araujo H., Danziger N., Cordier J., Glowinski J., and Chneiweiss H. (1993) Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J. Biol. Chem. 268, 5911 -5920.
56. Siegel R. M., Martin D. A., Zheng L., Ng S. Y., Bertin J., Cohen J., and Lenardo M. J. (1998) Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J. Cell Biol. 141, 1243-1253.
57. Newton K., Harris A. W., Bath M. L., Smith K. G., and Strasser A. (1998) A dominant interfering mutant of FADD/ MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17, 706-718.
58. Walsh C. M., Wen B. G., Chinnaiyan A. M., O'Rourke K., Dixit V. M., and Hedrick S. M. (1998) A role for FADD in T cell activation and development. Immunity 8, 439-449.
59. Zhang J., Kabra N. H., Cado D., Kang C., and Winoto A. (2001) FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J. Biol. Chem. 276, 29815-29818.
60. Hueber A. O., Zornig M., Bernard A. M., Chautan M., and Evan G. (2000) A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts. J. Biol. Chem. 275,10453-10462.
61. Kennedy N. J., Kataoka T., Tschopp J., and Budd R. C. (1999) Caspase activation is required for T cell proliferation. J. Exp. Med. 190,1891-1896.
62. Su H., Bidere N., Zheng L., Cubre A., Sakai K., Dale J., Salmena L., Hakem R., Straus S., and Lenardo M. (2005) Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 307, 1465-1468.
63. Posmantur R., Wang K. K., and Gilbertsen R. B. (1998) Caspase-3-like activity is necessary for IL-2 release in activated Jurkat T-cells. Exp. Cell Res. 244, 302-309.
64. Alam A., Cohen L. Y., Aouad S., and Sekaly R. P. (1999) Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190, 1879-1890.
65. Chun H. J., Zheng L., Ahmad M., Wang J., Speirs C. K., Siegel R. M., Dale J. K., Puck J., Davis J., Hall C. G., Skoda-Smith S., Atkinson T. P., Straus S. E., and Lenardo M. J. (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature, 419, 395-399.
66. Salmena L., Lemmers B., Hakem A., Matysiak-Zablocki E., Murakami K., Au P. Y., Berry D. M., Tamblyn L., Shehabel- din A., Migon E., Wakeham A., Bouchard D., Yeh W. C., McGlade J. C., Ohashi P. S., and Hakem R. (2003) Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev. 17, 883 - 895.
67. Kawadler H., Gantz M. A., Riley J. L., and Yang X. (2008) The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation. Mol. Cell 31, 415-421.
68. Chau H., Wong V., Chen N. J., Huang H. L., Lin W. J., Mirtsos C., Elford A. R., Bonnard M., Wakeham A., You-Ten A. I., Lemmers B., Salmena L., Pellegrini M., Hakem R., Mak T. W., Ohashi P., and Yeh W. C. (2005) Cellular FLICEinhibitory protein is required for T cell survival and cycling. J. Exp. Med. 202, 405-413.
69. Dohrman A., Kataoka T., Cuenin S., Russell J. Q., Tschopp J., and Budd R. C. (2005) Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF- kappa B activation. J. Immunol. 174, 5270-5278.
70. Arechiga A. F., Bell B. D., Solomon J. C., Chu I. H., Dubois C. L., Hall B. E., George T. C., Coder D. M., and Walsh C. M. (2005) Cutting edge: FADD is not required for antigen receptor-mediated NF-kappaB activation. J. Immunol. 175, 7800-7804.
71. Alderson M. R., Armitage R. J., Maraskovsky E., Tough T. W., Roux E., Schooley K., Ramsdell F., and Lynch D. H. (1993) Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178, 2231-2235.
72. Alappat E. C., Feig C., Boyerinas B., Volkland J., Samuels M., Murmann A. E., Thorburn A., Kidd V. J., Slaughter C. A., Osborn S. L., Winoto A., Tang W. J., and Peter M. E. (2005) Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol. Cell 19, 321 -332.
73. Scaffidi C., Volkland J., Blomberg I., Hoffmann I., Krammer P. H., and Peter M. E. (2000) Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle- regulated protein kinase. J. Immunol. 164,1236-1242.
74. Matsuyoshi S., Shimada K., Nakamura M., Ishida E., and Konishi N. (2006) FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br. J. Cancer 94, 532-539.
75. Zhang J., Zhang D., and Hua Z. (2004) FADD and its phosphorylation. IUBMB. Life, 56, 395 - 401.
76. Alappat E. C., Volkland J., and Peter M. E. (2003) Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site. J. Biol. Chem. 278, 41585-41588.
77. Rochat-Steiner V., Becker K., Micheau O., Schneider P., Burns K., and Tschopp J. (2000) FIST/HIPK3: a Fas/FADD- interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-termi- nal kinase activation. J. Exp. Med. 192,1165-1174.
78. Arai S., Miyake K., Voit R., Nemoto S., Wakeland E. K., Grummt I., and Miyazaki T. (2007) Death-effector domain- containing protein DEDD is an inhibitor of mitotic Cdk1/cyclin B1. Proc. Natl. Acad. Sci. USA 104, 2289-2294.
79. Miyazaki T. and AraiS. (2007) Two distinctcontrolsofmitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 6, 1419-1425.
80. Gilot D., Serandour A. L., Ilyin G. P., Lagadic-Gossmann D., Loyer P., Corlu A., Coutant A., Baffet G., Peter M. E., Fardel O., and Guguen-Guillouzo C. (2005) A role for caspase-8 and c-FLIPL in proliferation and cell-cycle progression of primary hepatocytes. Carcinogenesis, 26, 2086-2094.
81. Mogi M. and Togari A. (2003) Activation of caspases is required for osteoblastic differentiation. J. Biol. Chem. 278, 47477-47482.
82. Vaidyanathan H., Opoku-Ansah J., Pastorino S., Rengana- than H., Matter M. L., and Ramos J. W. (2007) ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15. Proc. Natl. Acad. Sci. USA 104, 19837-19842.
83. Vaidyanathan H. and Ramos J. W. (2003) RSK2 activity is regulated by its interaction with PEA-15. J. Biol. Chem. 278, 32367-32372.
84. Hauge C. and Frodin M. (2006) RSK and MSK in MAP kinase signalling. J. Cell Sci. 119, 3021-3023.
85. Schutze S., Tchikov V., and Schneider-Brachert W. (2008) Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat. Rev Mol. Cell Biol. 9, 655 -662.
86. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., and Schutze S. (2004) Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity. 21, 415-428.
87. Lee K. H., Feig C., Tchikov V., Schickel R., Hallas C., Schutze S., Peter M. E., and Chan A. C. (2006) The role of receptor internalization in CD95 signaling. EMBO J. 25, 1009-1023.
88. Ramos J. W., Kojima T. K., Hughes P. E., Fenczik C. A., and Ginsberg M. H. (1998) The death effector domain of PEA-15 is involved in its regulation of integrin activation. J. Biol. Chem. 273, 33897-33900.
89. Hughes P. E., Renshaw M. W., Pfaff M., Forsyth J., Keivens V. M., Schwartz M. A., and Ginsberg M. H. (1997) Suppression of integrin activation: a novel function of a Ras/Raf- initiated MAP kinase pathway. Cell 88, 521 -530.
90. Renault-Mihara F., Beuvon F., Iturrioz X., Canton B., De B. S., Leonard N., Mouhamad S., Sharif A., Ramos J. W., Junier M. P., and Chneiweiss H. (2006) PEA-15 Expression Inhibits Astrocyte Migration by a PKC Delta-Dependent Mechanism. Mol. Biol. Cell.
91. Glading A., Koziol J. A., Krueger J., and Ginsberg M. H. (2007) PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res. 67, 1536-1544.
92. Helfer B., Boswell B. C., Finlay D., Cipres A., Vuori K., Bong K. T., Wallach D., Dorfleutner A., Lahti J. M., Flynn D. C., and Frisch S. M. (2006) Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res. 66, 4273-4278.
93. Cursi S., Rufini A., Stagni V., Condo I., Matafora V., Bachi A., Bonifazi A. P., Coppola L., Superti-Furga G., Testi R., and Barila D. (2006) Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 25, 1895-1905.
94. Mitra S. K. and Schlaepfer D. D. (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516-523.
95. Senft J., Helfer B., and Frisch S. M. (2007) Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 67, 11505-11509.
96. Barbero S., Barila D., Mielgo A., Stagni V., Clair K., and Stupack D. (2008) Identification of a critical tyrosine residue in caspase 8 that promotes cell migration. J. Biol. Chem. 283, 13031-13034.
97. Finlay D. and Vuori K. (2007) Novel noncatalytic role for caspase-8 in promoting SRC-mediated adhesion and Erk signaling in neuroblastoma cells. Cancer Res. 67, 11704-11711.
98. Park D., Shim E., Kim Y., Kim Y. M., Lee H., Choe J., Kang D., Lee Y. S., and Jeoung D. (2008) C-FLIP promotes the motility of cancer cells by activating FAK and ERK., and increasing MMP-9 expression. Mol. Cells, 25, 184-195.
99. Barnhart B. C., Legembre P., Pietras E., Bubici C., Franzoso G., and Peter M. E. (2004) CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 23, 3175-3185.
100. Yeh W. C., Itie A., Elia A. J., Ng M., Shu H. B., Wakeham A., Mirtsos C., Suzuki N., Bonnard M., Goeddel D. V., and Mak T. W. (2000) Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity. 12, 633-642.
101. Yeh W. C., Pompa J. L., McCurrach M. E., Shu H. B., Elia A. J., Shahinian A., Ng M., Wakeham A., Khoo W., Mitchell K., El-Deiry W. S., Lowe S. W., Goeddel D. V., and Mak T. W. (1998) FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954-1958.
102. Varfolomeev E. E., Schuchmann M., Luria V., Chiannilkul- chai N., Beckmann J. S., Mett I. L., Rebrikov D., Brodianski V. M., Kemper O. C., Kollet O., Lapidot T., Soffer D., Sobe T., Avraham K. B., Goncharov T., Holtmann H., Lonai P., and WallachD. (1998) Targeted disruption of the mouse Caspase8 gene ablates cell death induction by the TNF receptors, Fas/ Apo1, and DR3 and is lethal prenatally. Immunity 9,267 - 276.
103. Wang J. and Lenardo M. J. (2000) Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J. Cell Sci. 113 (Pt 5), 753 -757.
104. Kim S. O., Ono K., and Han J. (2001) Apoptosis by pan- caspase inhibitors in lipopolysaccharide-activated macro-phages. Am. J. Physiol Lung Cell Mol. Physiol 281, L1095- L1105.
105. Sordet O., Rebe C., Plenchette S., Zermati Y., Hermine O., Vainchenker W., Garrido C., Solary E., and Dubrez-Daloz L. (2002) Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 100, 4446-4453.
106. Kang T. B., Ben-Moshe T., Varfolomeev E. E., Pewzner-Jung Y., Yogev N., Jurewicz A., Waisman A., Brenner O., Haffner R., Gustafsson E., Ramakrishnan P., Lapidot T., and Wallach D. (2004) Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173, 2976-2984.
107. Sanchez I., Xu C. J., Juo P., Kakizaka A., Blenis J., and Yuan J. (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22, 623-633.
108. Kalchman M. A., Koide H. B., McCutcheon K., Graham R. K., Nichol K., Nishiyama K., Kazemi-Esfarjani P., Lynn F. C., Wellington C., Metzler M., Goldberg Y. P., Kanazawa I., Gietz R. D., and Hayden M. R. (1997) HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane- associated huntingtin in the brain. Nat. Genet. 16, 44-53.
109. Gervais F. G., Singaraja R., Xanthoudakis S., Gutekunst C. A., Leavitt B. R., Metzler M., Hackam A. S., Tam J., Vaillancourt J. P., Houtzager V., Rasper D. M., Roy S., Hayden M. R., and Nicholson D. W. (2002) Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. 4, 95 -105.
110. Su H. C. and Lenardo M. J. (2008) Genetic defects of apoptosis and primary immunodeficiency. Immunol. Allergy Clin. North Am. 28, 329-51, ix.
111. Lenardo M., Chan K. M., Hornung F., McFarland H., Siegel R., Wang J., and Zheng L. (1999) Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17, 221 -253.
112. Straus S. E., Sneller M., Lenardo M. J., Puck J. M., and Strober W. (1999) An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann. Intern. Med. 130, 591 -601.
113. Wang J., Zheng L., Lobito A., Chan F. K., Dale J., Sneller M., Yao X., Puck J. M., Straus S. E., and Lenardo M. J. (1999) Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98, 47-58.
114. Fisher G. H., Rosenberg F. J., Straus S. E., Dale J. K., Middleton L. A., Lin A. Y., Strober W., Lenardo M. J., and Puck J. M. (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoprolifera-tive syndrome. Cell 81, 935-946.
115. Rieux-Laucat F., Le D. F., Hivroz C., Roberts I. A., Debatin K. M., Fischer A., and de Villartay J. P. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349.
116. Mogi M., Kinpara K., Kondo A., and Togari A. (1999) Involvement of nitric oxide and biopterin in proinflammatory cytokine-induced apoptotic cell death in mouse osteoblastic cell line MC3T3-E1. Biochem. Pharmacol. 58, 649-654.
117. Morimoto Y., Morimoto H., Murata T., Kobayashi S., Ohba T., and Haneji T. (1999) Extracts of Actinobacillus actino- mycetemcomitans induce apoptotic cell death in human osteoblastic MG63 cells. J. Dent. Res. 78, 735-742.
118. Yamamura Y., Gupta R., Morita Y., He X., Pai R., Endres J., Freiberg A., Chung K., and Fox D. A. (2001) Effector function of resting T cells: activation of synovial fibroblasts. J. Immunol. 166, 2270-2275.
119. Zhang J., Bardos T., Mikecz K., Finnegan A., and Glant T. T. (2001) Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J. Immunol. 166, 4981-4986.
120. Schirmer M., Vallejo A. N., Weyand C. M., and Goronzy J. J. (1998) Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+. J. Immunol. 161, 1018-1025.
121. Firestein G. S., Yeo M., and Zvaifler N. J. (1995) Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest, 96, 1631 -1638.
122. Catrina A. I., Ulfgren A. K., Lindblad S., Grondal L., and Klareskog L. (2002) Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann. Rheum. Dis. 61, 934-936.
123. Palao G., Santiago B., Galindo M., Paya M., Ramirez J. C., and Pablos J. L. (2004) Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis Rheum. 50, 2803 - 2810.
124. Palao G., Santiago B., Galindo M. A., Rullas J. N., Alcami J., Ramirez J. C., and Pablos J. L. (2006) Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum. 54, 1473-1481.
125. Kim P. K., Dutra A. S., Chandrasekharappa S. C., and Puck J. M. (1996) Genomic structure and mapping of human FADD., an intracellular mediator of lymphocyte apoptosis. J. Immunol. 157, 5461-5466.
126. Newton K., Harris A. W., and Strasser A. (2000) FADD/ MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor. EMBO J. 19, 931-941.
127. Tourneur L., Delluc S., Levy V., Valensi F., Radford-Weiss I., Legrand O., Vargaftig J., Boix C., Macintyre E. A., Varet B., Chiocchia G., and Buzyn A. (2004) Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res. 64, 8101 -8108.
128. Tourneur L., Mistou S., Michiels F. M., Devauchelle V., Renia L., Feunteun J., and Chiocchia G. (2003) Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 22, 2795-2804.
129. Gomez-Angelats M. and Cidlowski J. A. (2003) Molecular evidence for the nuclear localization of FADD. Cell Death Differ. 10, 791-797.
130. Screaton R. A., Kiessling S., Sansom O. J., Millar C. B., Maddison K., Bird A., Clarke A. R., and Frisch S. M. (2003) Fas-associated death domain protein interacts with methyl- CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc. Natl. Acad. Sci. USA 100, 5211 -5216.
131. Telliez J. B., Bean K. M., and Lin L. L. (2000) LRDD., a novel leucine rich repeat and death domain containing protein. Biochim. Biophys. Acta 1478, 280-288.
132. SheikhM.S. andHuangY. (2003) The FADD is going nuclear. Cell Cycle 2, 346-347.
133. Hua Z. C., Sohn S. J., Kang C., Cado D., and Winoto A. (2003) A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C- terminal region. Immunity 18, 513-521.
134. Chen G., Bhojani M. S., Heaford A. C., Chang D. C., Laxman B., Thomas D. G., Griffin L. B., Yu J., Coppola J. M., Giordano T. J., Lin L., Adams D., Orringer M. B., Ross B. D., Beer D. G., and Rehemtulla A. (2005) Phosphorylated FADD induces NF-kappaB., perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc. Natl. Acad. Sci. USA 102, 12507-12512.
135. Hopkins-Donaldson S., Bodmer J. L., Bourloud K. B., Brognara C. B., Tschopp J., and Gross N. (2000) Loss of caspase-8 expression in highly malignant human neuroblas- toma cells correlates with resistance to tumor necrosis factor- related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 60, 4315-4319.
136. Harada K., Toyooka S., Shivapurkar N., Maitra A., Reddy J. L., Matta H., Miyajima K., Timmons C. F., Tomlinson G. E., Mastrangelo D., Hay R. J., Chaudhary P. M., and Gazdar A. F. (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 62, 5897-5901.
137. Park W. S., Lee J. H., Shin M. S., Park J. Y., Kim H. S., Lee J. H., Kim Y. S., Lee S. N., Xiao W., Park C. H., Lee S. H., Yoo N. J., and Lee J. Y. (2002) Inactivating mutations of the caspase- 10 gene in gastric cancer. Oncogene, 21, 2919-2925.
138. McKee A. E. and Thiele C. J. (2006) Targeting caspase 8 to reduce the formation of metastases in neuroblastoma. Expert. Opin. Ther. Targets. 10, 703-708.
139. Lahti J. M., Teitz T., and Stupack D. G. (2006) Does integrin- mediated cell death confer tissue tropism in metastasis? Cancer Res. 66, 5981 -5984.
140. Formisano P., Perruolo G., Libertini S., Santopietro S., Troncone G., Raciti G. A., Oriente F., Portella G., Miele C., and Beguinot F. (2005) Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development. Oncogene 24, 7012-7021.
141. Stassi G., Garofalo M., Zerilli M., Ricci-Vitiani L., Zanca C., Todaro M., Aragona F., Limite G., Petrella G., and Condor- elli G. (2005) PED mediates AKT-dependent chemoresist- ance in human breast cancer cells. Cancer Res. 65,6668 - 6675.
142. Xiao C., Yang B. F., Asadi N., Beguinot F., and Hao C. (2002) Tumor necrosis factor-related apoptosis-inducing ligand-in- duced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 277, 25020-25025.
143. Hao C., Beguinot F., Condorelli G., Trencia A., Van Meir E. G., Yong V. W., Parney I. F., Roa W. H., and Petruk K. C. (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 61, 1162-1170.
144. Zanca C., Garofalo M., Quintavalle C., Romano G., Acunzo M., Ragno P., Montuori N., Incoronato M. R., Tornillo L., Baumhoer D., Briguori C., Terracciano L., and Condorelli G. (2008) PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. J. Cell Mol. Med.[Epub ahead of print] doi: 10.1111/j.1582-4934.2008.00283.x.
145. Garofalo M., Romano G., Quintavalle C., Romano M. F., Chiurazzi F., Zanca C., and Condorelli G. (2007) Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Int. J. Cancer 120, 1215-1222.
146. Eckert A., Bock B. C., Tagscherer K. E., Haas T. L., Grund K., Sykora J., Herold-Mende C., Ehemann V., Hollstein M., Chneiweiss H., Wiestler O. D., Walczak H., and Roth W. (2008) The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/ MAP kinase pathway. Oncogene 27, 1155-1166.
147. Condorelli G., Vigliotta G., Iavarone C., Caruso M., Toc- chetti C. G., Andreozzi F., Cafieri A., Tecce M. F., Formisano P., Beguinot L., and Beguinot F. (1998) PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J. 17, 3858-3866.
148. Vigliotta G., Miele C., Santopietro S., Portella G., Perfetti A., Maitan M. A., Cassese A., Oriente F., Trencia A., Fiory F., Romano C., Tiveron C., Tatangelo L., Troncone G., Formi- sano P., and Beguinot F. (2004) Overexpression of the ped/ pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action. Mol. Cell Biol. 24, 5005-5015.
149. Bartholomeusz C., Itamochi H., Nitta M., Saya H., Ginsberg M. H., and Ueno N. T. (2006) Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25, 79-90.
150. Gaumont-Leclerc M. F., Mukhopadhyay U. K., Goumard S., and Ferbeyre G. (2004) PEA-15 is inhibited by adenovirus E1A and plays a role in ERK nuclear export and Ras-induced senescence. J. Biol. Chem. 279, 46802-46809.
151. Shisler J. L. and Moss B. (2001) Molluscum contagiosum virus inhibitors of apoptosis: The MC159 v-FLIP protein blocks Fas-induced activation of procaspases and degradation of the related MC160 protein. Virology 282, 14-25.
152. Nichols D. B. and Shisler J. L. (2006) The MC160 protein expressed by the dermatotropic poxvirus molluscum conta- giosum virus prevents tumor necrosis factor alpha-induced NF-kappaB activation via inhibition of I kappa kinase complex formation. J. Virol. 80, 578-586.
153. Chaudhary P. M., Jasmin A., Eby M. T., and Hood L. (1999) Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18, 5738-5746.
154. Thurau M., Everett H., Tapernoux M., Tschopp J., and Thome M. (2006) The TRAF3-binding site of human molluscipox virus FLIP molecule MC159 is critical for its capacity to inhibit Fas-induced apoptosis. Cell Death Differ. 13, 1577-1585.
155. Boshoff C. and Chang Y. (2001) Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu. Rev. Med. 52, 453-470.
156. Dourmishev L. A., Dourmishev A. L., Palmeri D., Schwartz R. A., and Lukac D. M. (2003) Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 175-212, table.
157. Herndier B. and Ganem D. (2001) The biology of Kaposi's sarcoma. Cancer Treat. Res. 104, 89-126.
158. Djerbi M., Screpanti V., Catrina A. I., Bogen B., Biberfeld P., and Grandien A. (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190,1025-1032.
159. Matta H., Surabhi R. M., Zhao J., PunjV., Sun Q., Schamus S., Mazzacurati L., and Chaudhary P. M. (2007) Induction of spindle cell morphology in human vascular endothelial cells by human herpesvirus 8-encoded viral FLICE inhibitory protein K13. Oncogene 26,1656-1660.
160. Sun Q., Matta H., Lu G., and Chaudhary P. M. (2006) Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. Oncogene 25, 2717-2726.
161. Chugh P., Matta H., Schamus S., Zachariah S., Kumar A., Richardson J. A., Smith A. L., and Chaudhary P. M. (2005) Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc. Natl. Acad. Sci. USA 102,12885-12890.
162. Sun Q., Matta H., and Chaudhary P. M. (2005) Kaposi's sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat. Retrovirology 2, 9.
163. Matta H., Mazzacurati L., Schamus S., Yang T., Sun Q., and Chaudhary P. M. (2007) Kaposi's sarcoma-associated herpes- virus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation. J. Biol. Chem. 282, 24858-24865.
164. Matta H., PunjV., Schamus S., Mazzacurati L., Chen A. M., Song R., Yang T., and Chaudhary P. M. (2008) A nuclear role for Kaposi's sarcoma-associated herpesvirus-encoded K13 protein in gene regulation. Oncogene 27, 5243 - 5253.
165. Hill J. M., Vaidyanathan H., Ramos J. W., Ginsberg M. H., and Werner M. H. (2002) Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. EMBO J. 21, 6494-6504.